Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus.

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

Benfotiamine

Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day

DIETARY_SUPPLEMENT

Placebo

Placebo 900 mg per day

Trial Locations (1)

37320

Department of Medical Sciences, University of Guanajuato, León Mexico, León

All Listed Sponsors
lead

Universidad de Guanajuato

OTHER

NCT02772926 - Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus. | Biotech Hunter | Biotech Hunter